Correlation between matrix metalloproteinase 9 and 18F-2-fluoro-2-deoxyglucose-positron emission tomography as diagnostic markers of lung cancer

European Journal of Cardio-thoracic Surgery

Volumn 41, Issue 4, 2012, Pages 852-860

  Fiorelli, Alfonso ^a   Rizzo, Antonietta ^a   Messina, Gaetana ^a   Izzo, Anna ^a   Vicidomini, Giovanni ^a   Pannone, Giuseppe ^b   Santini, Mario ^a   Domenico, Marina Di ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Lung cancer; Matrix metalloproteinase 9

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GELATINASE B; TUMOR MARKER; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER STAGING; DIAGNOSTIC ACCURACY; DRUG UPTAKE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; BLOOD; CHEMISTRY; EVALUATION; LUNG TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SCINTISCANNING; VITAL CAPACITY;

ADULT; AGED; AGED, 80 AND OVER; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; FLUORODEOXYGLUCOSE F18; FORCED EXPIRATORY VOLUME; HUMANS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; TUMOR MARKERS, BIOLOGICAL; VITAL CAPACITY;

EID: 84862319031     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezr117     Document Type: Article

References (25)

1. Gould MK, Fletcher J, Iannettoni MD, Lynch WR, Midthun DE, Naidich DP et al. Evaluation of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:108S-30S.
2. Kahn N, Kuner R, Eberhardt R, Meister M, Muley T, Winteroll S et al. Gene expression analysis of endobronchial epithelial lining fluid in the evaluation of indeterminate pulmonary nodules. J Thorac Cardiovasc Surg 2009;138:474-9.
3. Truong MT, Viswanathan C, Erasmus JJ. Positron emission tomography/ computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response. J Thorac Imaging 2011;26:132-46.
4. Cheran SK, Nielsen ND, Patz EF Jr. False-negative findings for primary lung tumors on FDG positron emission tomography: staging and prognostic implications. Am J Roentgenol 2004;182:1129-32.
5. Leinonen T, Pirinen R, Böhm J, Johansson R, Ropponen K, Kosma VM. Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer. Relation to clinicopathological factors, beta-catenin and prognosis. Lung Cancer 2006;51:313-21.
6. Ondo K, Sugio K, Yamazaki K, Yamaguchi M, Yano T, Yoshino I et al. The significance of serum active matrix metalloproteinase-9 in patients with non-small cell lung cancer. Lung Cancer 2004;46:205-13.
7. Giroux DJ, Rami-Porta R, Chansky K, Crowley JJ, Groome PA, Postmus PE et al. The IASLC Lung Cancer Staging Project: data elements for the prospective project. J Thorac Oncol 2009;4:679-83.
8. Laack E, Köhler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel G et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 2002;13:1550-7.
9. Jumper C, Cobos E, Lox C. Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respir Med 2004;98:173-7.
10. Iizasa T, Fujisawa T, Suzuki M, Motohashi S, Yasufuku K, Yasukawa T et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in nonsmall cell lung cancer patients. Clin Cancer Res 1999;5:149-53.
11. Koç M, Ediger D, Budak F, Karada M, Oral HB, Uzaslan E et al. Matrix metalloproteinase-9 (MMP-9) elevated in serum but not in bronchial lavage fluid in patients with lung cancer. Tumori 2006;92:149-54.
12. Ylisirniö S, Höyhtyä M, Mäkitaro R, Pääakkö P, Risteli J, Kinnula VL et al. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 2001;7:1633-7.
13. van Kempen LC, Coussens LM. MMP9 potentiates pulmonary metastasis formation. Cancer Cell 2002;2:251-2.
14. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002;2:289-300.
15. Hrabec E, Strek M, Nowak D, Hrabec Z. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Respir Med 2001;95:1-4.
16. Atkinson JJ, Senior RM. Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol 2003;28:12-24.
17. Finlay GA, Russell KJ, McMahon KJ, D'arcy EM, Masterson JB, FitzGerald MX et al. Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax 1997;52:502-6.
18. Kodate M, Kasai T, Hashimoto H, Yasumoto K, Iwata Y, Manabe H. Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol Int 1997;47:461-9.
19. Cox G, Jones JL, O'Byrne KJ. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 2000;6:2349-55.
20. Goodgame B, Pillot GA, Yang Z, Shriki J, Meyers BF, Zoole J et al. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. J Thorac Oncol 2008;3: 130-4.
21. Hanin FX, Lonneux M, Cornet J, Noirhomme P, Coulon C, Distexhe J et al. Prognostic value of FDG uptake in early stage non-small cell lung cancer. Eur J Cardiothorac Surg 2008;33:819-23.
22. Ohtsuka T, Nomori H, Watanabe K, Kaji M, Naruke T, Suemasu K et al. Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer 2006;107:2468-73.
23. Grogan EL, Deppen S, Pecot CV, Putnam JB Jr, Nesbitt JC, Shyr Y et al. Diagnostic characteristics of a serum biomarker in patients with positron emission tomography scans. Ann Thorac Surg 2010;89:1724-8.
24. Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999;354:99-105.
25. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001;285:914-24.